Exatecan (BioDeep_00000706867)
代谢物信息卡片
化学式: C24H22FN3O4 (435.15942640000003)
中文名称: 依喜替康
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCC1(C2=C(COC1=O)C(=O)N3CC4=C5C(CCC6=C5C(=CC(=C6C)F)N=C4C3=C2)N)O
InChI: InChI=1S/C24H22FN3O4/c1-3-24(31)14-6-18-21-12(8-28(18)22(29)13(14)9-32-23(24)30)19-16(26)5-4-11-10(2)15(25)7-17(27-21)20(11)19/h6-7,16,31H,3-5,8-9,26H2,1-2H3/t16-,24-/m0/s1
描述信息
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059004 - Topoisomerase I Inhibitors
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor
D004791 - Enzyme Inhibitors
同义名列表
2 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- ChEBI: CHEBI:135709
- PubChem: 151115
- DrugBank: DB12185
- ChEMBL: CHEMBL1614650
- CAS: 171335-80-1
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:
- PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。
文献列表
- Ukhyun Jo, Yasuhisa Murai, Keli K Agama, Yilun Sun, Liton Kumar Saha, Xi Yang, Yasuhiro Arakawa, Sophia Gayle, Kelli Jones, Vishwas Paralkar, Ranjini K Sundaram, Jinny Van Doorn, Juan C Vasquez, Ranjit S Bindra, Woo Suk Choi, Yves Pommier. TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor.
Molecular cancer therapeutics.
2022 07; 21(7):1090-1102. doi:
10.1158/1535-7163.mct-21-1000
. [PMID: 35439320] - R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals.
2008 Jul; 36(7):1385-405. doi:
10.1124/dmd.108.020479
. [PMID: 18426954] - Jaffer A Ajani, Chris Takimoto, Carlos R Becerra, Alejandro Silva, Luis Baez, Allen Cohn, Pierre Major, Makio Kamida, Kevie Feit, Robert De Jager. A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer.
Investigational new drugs.
2005 Oct; 23(5):479-84. doi:
10.1007/s10637-005-2907-z
. [PMID: 16133799] - Moritz N Wente, Jörg Kleeff, Markus W Büchler, Jantien Wanders, Peter Cheverton, Stephen Langman, Helmut Friess. DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors.
Investigational new drugs.
2005 Aug; 23(4):339-47. doi:
10.1007/s10637-005-1442-2
. [PMID: 16012793] - Toshihiro Oguma, Dino Cicci, Fleur Gaudette, Ginette Gauthier-Dubois, Rudolf Guilbaud, Ryo Atsumi. Validation study of a method for assaying DE-310, a macromolecular carrier conjugate containing an anti-tumor camptothecin derivative, and the free drug in human plasma by HPLC and LC/MS/MS.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2005 Apr; 818(2):249-56. doi:
10.1016/j.jchromb.2005.01.005
. [PMID: 15734166] - Yusuke Ochi, Yoshinobu Shiose, Hiroshi Kuga, Eiji Kumazawa. A possible mechanism for the long-lasting antitumor effect of the macromolecular conjugate DE-310: mediation by cellular uptake and drug release of its active camptothecin analog DX-8951.
Cancer chemotherapy and pharmacology.
2005 Apr; 55(4):323-332. doi:
10.1007/s00280-004-0911-1
. [PMID: 15517271] - N Masubuchi. Pharmacokinetics of DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f, in tumor-bearing mice.
Die Pharmazie.
2004 May; 59(5):374-7. doi:
NULL
. [PMID: 15212304] - Claire F Verschraegen, Andrzej P Kudelka, Wei Hu, Monique Vincent, John J Kavanagh, Evelyne Loyer, Luc Bastien, A Duggal, R De Jager. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.
Cancer chemotherapy and pharmacology.
2004 Jan; 53(1):1-7. doi:
10.1007/s00280-003-0696-7
. [PMID: 14586557] - Melanie E Royce, Eric K Rowinsky, Paulo M Hoff, John Coyle, Robert DeJager, Richard Pazdur, Leonard B Saltz. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectum.
Investigational new drugs.
2004 Jan; 22(1):53-61. doi:
10.1023/b:drug.0000006174.87869.6b
. [PMID: 14707494] - Francisco J Esteva, Edgardo Rivera, Massimo Cristofanilli, Vicente Valero, Melanie Royce, Anil Duggal, Philippe Colucci, Robert DeJager, Gabriel N Hortobagyi. A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma.
Cancer.
2003 Sep; 98(5):900-7. doi:
10.1002/cncr.11557
. [PMID: 12942555] - Mitchell A Garrison, Lisa A Hammond, Charles E Geyer, Garry Schwartz, Anthony W Tolcher, Leslie Smetzer, Jose A Figueroa, Murray Ducharme, John Coyle, Chris H Takimoto, Robert L De Jager, Eric K Rowinsky. A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2003 Jul; 9(7):2527-37. doi:
NULL
. [PMID: 12855627] - J P Braybrooke, E Boven, N P Bates, R Ruijter, N Dobbs, P D Cheverton, H M Pinedo, D C Talbot. Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology.
2003 Jun; 14(6):913-21. doi:
10.1093/annonc/mdg243
. [PMID: 12796030] - S Sharma, N Kemeny, G K Schwartz, D Kelsen, E O'Reilly, D Ilson, J Coyle, R L De Jager, M P Ducharme, S Kleban, E Hollywood, L B Saltz. Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2001 Dec; 7(12):3963-70. doi:
NULL
. [PMID: 11751488] - T Oguma, T Konno, A Inaba, M Nakaoka. Validation study of assay method for DX-8951 and its metabolite in human plasma and urine by high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry.
Biomedical chromatography : BMC.
2001 Apr; 15(2):108-15. doi:
10.1002/bmc.44
. [PMID: 11268051] - M E Royce, P M Hoff, P Dumas, Y Lassere, J J Lee, J Coyle, M P Ducharme, R De Jager, R Pazdur. Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2001 Mar; 19(5):1493-500. doi:
10.1200/jco.2001.19.5.1493
. [PMID: 11230496] - T Oguma, M Yamada, T Konno, K Inukai, M Nakaoka. High-Performance liquid chromatographic analysis of lactone and hydroxy acid of new antitumor drug, DX-8951 (exatecan), in mouse plasma.
Biological & pharmaceutical bulletin.
2001 Feb; 24(2):176-80. doi:
10.1248/bpb.24.176
. [PMID: 11217088] - V Boige, E Raymond, S Faivre, M Gatineau, K Meely, S Mekhaldi, P Pautier, M Ducreux, O Rixe, J P Armand. Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2000 Dec; 18(23):3986-92. doi:
10.1200/jco.2000.18.23.3986
. [PMID: 11099328] - T Oguma, Y Ohshima, M Nakaoka. Sensitive high-performance liquid chromatographic method for the determination of the lactone form and the lactone plus hydroxy-acid forms of the new camptothecin derivative DX-8951 in human plasma using fluorescence detection.
Journal of chromatography. B, Biomedical sciences and applications.
2000 Apr; 740(2):237-45. doi:
10.1016/s0378-4347(00)00108-0
. [PMID: 10821410] - R A Lawrence, E Izbicka, R L De Jager, A Tohgo, G M Clark, S D Weitman, E K Rowinsky, D D Von Hoff. Comparison of DX-8951f and topotecan effects on tumor colony formation from freshly explanted adult and pediatric human tumor cells.
Anti-cancer drugs.
1999 Aug; 10(7):655-61. doi:
10.1097/00001813-199908000-00005
. [PMID: 10507315] - E Kumazawa, T Jimbo, Y Ochi, A Tohgo. Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice.
Cancer chemotherapy and pharmacology.
1998; 42(3):210-20. doi:
10.1007/s002800050807
. [PMID: 9685056]